Detection of CD34+CD38−LSCs and their expression on CD123+ and CD 96+ with their clinical impact in AML patients before and after chemotherapy.

Acute myeloid leukemia (AML) is characterized by the overproduction and accumulation of immature blast cells, specifically myeloid precursors with the stander strategy of therapy patients achieve remission but the majority of them relapse of some of them are resistant to therapy. The cases of relapse and resistance it believed to back to the present of small subpopulations called leukemic stem cells (LSCs) the current study aimed to identify LSCs in patients with AML and their correlation with treatment protocols outcomes status, patient's characterization, and subtype of AML and to evaluate the expression CD123 and CD96 on CD34+CD38- blast cells by flow-cytometry for the patients that diagnosed with AML before and after chemotherapy, The expressions of CD34+/CD38- cells in blood samples of newly diagnosed constitutes about 61.1 ± 7.8% from all hematopoietic cells, which is significantly (P= 0.013) higher than those in treated patients that constitutes about 40.5 ± 3.7% from all hematopoietic cells in their blood samples. Out of all CD34+/CD38- cells, the result showed that 53.7 ± 8.8% of them also expressed CD123+ in blood samples of newly diagnosed AML patients, which is significantly (P< 0.0001) higher than those in blood samples of treated patients (19.9 ± 3.1%) and the expression of CD96+ in blood samples of newly diagnosed AML patients, which is significantly (P< 0.002) higher than those in blood samples of treated patients (16.8 ± 2.2%) the data results propose that these LSCs can be the reason for disease recurrence and also can be good therapeutic targets. [ABSTRACT FROM AUTHOR]